Trials / Conditions / House Dust Mite Allergy

House Dust Mite Allergy

23 registered clinical trials studyying House Dust Mite Allergy — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects NCT06803953	Hippocreates	N/A
Active Not Recruiting	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mi NCT06920771	HAL Allergy	Phase 3
Unknown	Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivit NCT05400811	Inmunotek S.L.	Phase 3
Unknown	The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunoth NCT05450289	Universitas Airlangga	N/A
Recruiting	Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM NCT05395689	Probelte Pharma S.L.U.	Phase 3
Completed	Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients NCT05019209	Fraunhofer-Institute of Toxicology and Experimental Medicine	N/A
Unknown	Epigenetic Regulation of Exercise Induced Asthma NCT05174689	Johann Wolfgang Goethe University Hospital	N/A
Terminated	Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis NCT04874714	Inmunotek S.L.	Phase 3
Completed	Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy NCT04435678	MacroArray Diagnostics GmbH	N/A
Completed	Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients NCT03094845	ASIT Biotech S.A.	Phase 2
Completed	Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-ass NCT02443805	Stallergenes Greer	Phase 3
Completed	SUBLIVAC FIX Mite Mixture Dose Tolerability Study NCT02345278	HAL Allergy	Phase 1 / Phase 2
Unknown	AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness NCT02238353	Universitaire Ziekenhuizen KU Leuven	Phase 4
Completed	ToleroMune House Dust Mite Follow on Study NCT01923792	Circassia Limited	—
Completed	Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Al NCT01930461	Stallergenes Greer	Phase 2
Terminated	Role of the Central Nervous System in Allergic Rhinitis NCT01777464	Universitaire Ziekenhuizen KU Leuven	N/A
Completed	Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts NCT01608243	Stallergenes Greer	Phase 1
Completed	A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet NCT01454544	ALK-Abelló A/S	Phase 3
Completed	Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. NCT01134757	Johann Wolfgang Goethe University Hospital	N/A
Completed	A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivit NCT00574223	Cytos Biotechnology AG	Phase 2
Completed	A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivit NCT00574704	Cytos Biotechnology AG	Phase 2
Completed	Fish Oil and Asthma in House Dust Mite Allergy NCT00380926	Johann Wolfgang Goethe University Hospital	Phase 2 / Phase 3
Completed	Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis NCT00263549	Allergopharma GmbH & Co. KG	Phase 4